A new analysis published in Diabetes Therapy found that people with type 2 diabetes using basal insulin had better blood sugar control and greater weight loss when tirzepatide was added to their treatment. Compared to older GLP-1 drugs, tirzepatide produced stronger results while maintaining a similar safety profile, offering a promising option for improved diabetes care.